Plasma Thrombin-activatable Fibrinolysis Inhibitor Levels Correlate with the Disease Activity of Ulcerative Colitis

BEYAZIT Y., Sayilir A., Tanoglu A., Kekilli M., Kocak E., Ekiz F., ...Daha Fazla

INTERNAL MEDICINE, cilt.55, sa.14, ss.1831-1836, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 55 Sayı: 14
  • Basım Tarihi: 2016
  • Doi Numarası: 10.2169/internalmedicine.55.6473
  • Dergi Adı: INTERNAL MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1831-1836
  • Anahtar Kelimeler: plasma thrombin-activatable fibrinolysis inhibitor, ulcerative colitis, treatment, INFLAMMATORY-BOWEL-DISEASE, TAFI, COAGULATION, MARKERS, TRIAL
  • Gazi Üniversitesi Adresli: Hayır

Özet

Objective Patients with ulcerative colitis (UC) are at an increased risk for thromboembolic events, particularly in patients with extensive and active disease. To date, a few studies have been published on the role of thrombin-activatable fibrinolysis inhibitor (TAFI) in UC. However, there are no reports in the literature investigating the effect of UC treatment on plasma TAFI levels.